At a glance
- Originator LEO Pharma
- Class Anti-inflammatories; Benzoic acids
- Mechanism of Action Arachidonic acid inhibitors; Leukotriene B4 receptor antagonists; Leukotriene D4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation; Skin disorders
Most Recent Events
- 09 Nov 2000 Discontinued-Preclinical for Inflammation in Denmark (Topical)
- 09 Nov 2000 Discontinued-Preclinical for Skin disorders in Denmark (Topical)
- 07 Sep 1998 No-Development-Reported for Inflammation in Denmark (Topical)